TPST TEMPEST THERAPEUTICS INC

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:30 am ET.

To access the live or archived recording of the chat, please visit the investor section of the Tempest website at .

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both programs are advancing through clinical trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at .

Investor Contacts:

Sylvia Wheeler

Wheelhouse Life Science Advisors

Aljanae Reynolds

Wheelhouse Life Science Advisors



EN
22/11/2022

Underlying

TPSTTEMPEST THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEMPEST THERAPEUTICS INC

 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Reports Year End 2025 Financial Results and Provides Business ...

Tempest Reports Year End 2025 Financial Results and Provides Business Update Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candid...

March 30, 2026 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Therapeutics Announces Up To $6 Million Private Placement

Tempest Therapeutics Announces Up To $6 Million Private Placement $2 million upfront with up to approximately $4 million of potential aggregate gross proceeds upon the exercise in full of warrants BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 925,927 shares of common stock (or pre-funded wa...

March 23, 2026 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Announces Partnership for TPST-2003 in Preparation for Planned...

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 Cincinnati Children’s Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned to be complete in Q3 2026 to support potential IND filing in Q4 2026Selection of tech transfer partner follows Tempest’s recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% CR in all six efficacy evaluable patients, and accelerat...

March 11, 2026 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-...

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, including in patients with extramedullary disease36 patients with relapsed/refractory multiple myeloma treated to date across two studiesTempest plans to submit a U.S. IND and, subject to clearance, initiate a U.S. registrational s...

February 25, 2026 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targ...

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assetsDevelopment approach prioritizes partner-funded and externally supported programs to generate clinical data before deploying significant internal capitalPipeline expansion includes TPST-4003, an in vivo dual-targeting CD19/BCMA CAR-T, with potential near-term milestones BRISBANE, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TP...

February 11, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch